---
document_datetime: 2025-12-17 23:15:16
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/darunavir-viatris.html
document_name: darunavir-viatris.html
version: success
processing_time: 0.1312075
conversion_datetime: 2025-12-28 18:13:54.108997
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Darunavir Viatris (previously Darunavir Mylan)

[RSS](/en/individual-human-medicine.xml/66108)

##### Authorised

This medicine is authorised for use in the European Union

darunavir Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Darunavir Viatris (previously Darunavir Mylan)](#news-on)
- [More information on Darunavir Mylan](#more-information-on-darunavir-mylan-1203)
- [Related information](#related-information-616)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Darunavir Viatris is an antiviral medicine used with other HIV medicines to treat patients with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS). It is given with low-dose ritonavir or, in adults, with cobicistat. Darunavir Viatris may be given to adults or children from 3 years of age and weighing at least 15 kg.

Darunavir Viatris contains the active substance darunavir and is a 'generic medicine'. This means that Darunavir Viatris contains the same active substance and works in the same way as a 'reference medicine' already authorised in the EU. The reference medicine for Darunavir Viatris is Prezista. For more information on generic medicines, see the question-and-answer document [here](https://www.ema.europa.eu/en/documents/other/questions-and-answers-generic-medicines_en.pdf) .

Expand section

Collapse section

## How is Darunavir Viatris used?

Darunavir Viatris can only be obtained with a prescription and treatment should be started by a healthcare professional who has experience in the management of HIV infection.

Darunavir Viatris is available as tablets. The medicine is always taken either with cobicistat (in adults) or with low-dose ritonavir (in adults and children) and with other HIV medicines, and should be taken with food.

For more information about using Darunavir Viatris, see the package leaflet or contact your doctor or pharmacist

## How does Darunavir Viatris work?

The active substance in Darunavir Viatris, darunavir, is a protease inhibitor. It blocks protease, an enzyme involved in the reproduction of HIV. When the enzyme is blocked, the virus does not reproduce normally, slowing down its multiplication in the body. Darunavir Viatris is always given with ritonavir or cobicistat. Ritonavir and cobicistat reduce the breakdown of darunavir, increasing the levels of darunavir in the blood. This allows effective treatment while avoiding a higher dose of darunavir.

Darunavir Viatris, taken in combination with other HIV medicines, reduces the amount of HIV in the blood and keeps it at a low level. Darunavir Viatris does not cure HIV infection or AIDS, but HIV treatment may hold off the damage to the immune system and the development of infections and diseases associated with AIDS.

## How has Darunavir Viatris been studied?

Studies on the benefits and risks of the active substance in the approved use have already been carried out with the reference medicine, Prezista, and do not need to be repeated for Darunavir Viatris.

As for every medicine, the company provided studies on the quality of Darunavir Viatris. The company also carried out studies that showed that it is 'bioequivalent' to the reference medicine. Two medicines are bioequivalent when they produce the same levels of the active substance in the body and are therefore expected to have the same effect.

## What are the benefits and risks of Darunavir Viatris?

Because Darunavir Viatris is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Darunavir Viatris authorised in the EU?

The European Medicines Agency concluded that, in accordance with EU requirements, Darunavir Viatris has been shown to have comparable quality and to be bioequivalent to Prezista. Therefore, the Agency's view was that, as for Prezista, the benefit outweighs the identified risk and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Darunavir Viatris?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Darunavir Viatris have been included in the summary of product characteristics and the package leaflet. Any additional measures in place for Prezista also apply to Duranavir Viatris where appropriate.

As for all medicines, data on the use of Duranavir Viatris are continuously monitored. Suspected side effects reported with Duranavir Viatris are carefully evaluated and any necessary action taken to protect patients.

## Other information about Darunavir Viatris

The European Commission granted a marketing authorisation valid throughout the European Union for Darunavir Mylan on 4 January 2017.

The name of the medicine was changed to Duranavir Viatris on 5 July 2024.

Darunavir Viatris : EPAR - Medicine overview

Reference Number: EMA/284786/2024

English (EN) (132.11 KB - PDF)

**First published:** 03/02/2017

**Last updated:** 08/01/2025

[View](/en/documents/overview/darunavir-viatris-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-309)

български (BG) (157.77 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

08/01/2025

[View](/bg/documents/overview/darunavir-mylan-epar-summary-public_bg.pdf)

español (ES) (133.2 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

08/01/2025

[View](/es/documents/overview/darunavir-mylan-epar-summary-public_es.pdf)

čeština (CS) (154.37 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

08/01/2025

[View](/cs/documents/overview/darunavir-mylan-epar-summary-public_cs.pdf)

dansk (DA) (131.7 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

08/01/2025

[View](/da/documents/overview/darunavir-mylan-epar-summary-public_da.pdf)

Deutsch (DE) (136.55 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

08/01/2025

[View](/de/documents/overview/darunavir-mylan-epar-summary-public_de.pdf)

eesti keel (ET) (129.98 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

08/01/2025

[View](/et/documents/overview/darunavir-mylan-epar-summary-public_et.pdf)

ελληνικά (EL) (157.54 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

08/01/2025

[View](/el/documents/overview/darunavir-mylan-epar-summary-public_el.pdf)

français (FR) (134.52 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

08/01/2025

[View](/fr/documents/overview/darunavir-mylan-epar-summary-public_fr.pdf)

hrvatski (HR) (152.4 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

08/01/2025

[View](/hr/documents/overview/darunavir-mylan-epar-summary-public_hr.pdf)

italiano (IT) (131.29 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

08/01/2025

[View](/it/documents/overview/darunavir-mylan-epar-summary-public_it.pdf)

latviešu valoda (LV) (170.57 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

08/01/2025

[View](/lv/documents/overview/darunavir-mylan-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (153.82 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

08/01/2025

[View](/lt/documents/overview/darunavir-mylan-epar-summary-public_lt.pdf)

magyar (HU) (154.88 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

08/01/2025

[View](/hu/documents/overview/darunavir-mylan-epar-summary-public_hu.pdf)

Malti (MT) (156.05 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

08/01/2025

[View](/mt/documents/overview/darunavir-mylan-epar-summary-public_mt.pdf)

Nederlands (NL) (133.64 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

08/01/2025

[View](/nl/documents/overview/darunavir-mylan-epar-summary-public_nl.pdf)

polski (PL) (157.51 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

08/01/2025

[View](/pl/documents/overview/darunavir-mylan-epar-summary-public_pl.pdf)

português (PT) (134.17 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

08/01/2025

[View](/pt/documents/overview/darunavir-mylan-epar-summary-public_pt.pdf)

română (RO) (153.22 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

08/01/2025

[View](/ro/documents/overview/darunavir-mylan-epar-summary-public_ro.pdf)

slovenčina (SK) (153.95 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

08/01/2025

[View](/sk/documents/overview/darunavir-mylan-epar-summary-public_sk.pdf)

slovenščina (SL) (150.23 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

08/01/2025

[View](/sl/documents/overview/darunavir-mylan-epar-summary-public_sl.pdf)

Suomi (FI) (130.1 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

08/01/2025

[View](/fi/documents/overview/darunavir-mylan-epar-summary-public_fi.pdf)

svenska (SV) (130.31 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

08/01/2025

[View](/sv/documents/overview/darunavir-mylan-epar-summary-public_sv.pdf)

Darunavir Mylan : EPAR - Risk-management-plan summary

English (EN) (108.54 KB - PDF)

**First published:** 16/02/2021

[View](/en/documents/rmp-summary/darunavir-mylan-epar-risk-management-plan-summary_en.pdf)

## Product information

Darunavir Viatris : EPAR - Product Information

English (EN) (968.77 KB - PDF)

**First published:** 03/02/2017

**Last updated:** 11/12/2025

[View](/en/documents/product-information/darunavir-viatris-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-697)

български (BG) (1.3 MB - PDF)

**First published:**

03/02/2017

**Last updated:**

11/12/2025

[View](/bg/documents/product-information/darunavir-viatris-epar-product-information_bg.pdf)

español (ES) (1.12 MB - PDF)

**First published:**

03/02/2017

**Last updated:**

11/12/2025

[View](/es/documents/product-information/darunavir-viatris-epar-product-information_es.pdf)

čeština (CS) (1.18 MB - PDF)

**First published:**

03/02/2017

**Last updated:**

11/12/2025

[View](/cs/documents/product-information/darunavir-viatris-epar-product-information_cs.pdf)

dansk (DA) (1.08 MB - PDF)

**First published:**

03/02/2017

**Last updated:**

11/12/2025

[View](/da/documents/product-information/darunavir-viatris-epar-product-information_da.pdf)

Deutsch (DE) (1.18 MB - PDF)

**First published:**

03/02/2017

**Last updated:**

11/12/2025

[View](/de/documents/product-information/darunavir-viatris-epar-product-information_de.pdf)

eesti keel (ET) (1.03 MB - PDF)

**First published:**

03/02/2017

**Last updated:**

11/12/2025

[View](/et/documents/product-information/darunavir-viatris-epar-product-information_et.pdf)

ελληνικά (EL) (1.36 MB - PDF)

**First published:**

03/02/2017

**Last updated:**

11/12/2025

[View](/el/documents/product-information/darunavir-viatris-epar-product-information_el.pdf)

français (FR) (1.14 MB - PDF)

**First published:**

03/02/2017

**Last updated:**

11/12/2025

[View](/fr/documents/product-information/darunavir-viatris-epar-product-information_fr.pdf)

hrvatski (HR) (1.07 MB - PDF)

**First published:**

03/02/2017

**Last updated:**

11/12/2025

[View](/hr/documents/product-information/darunavir-viatris-epar-product-information_hr.pdf)

íslenska (IS) (1.01 MB - PDF)

**First published:**

03/02/2017

**Last updated:**

11/12/2025

[View](/is/documents/product-information/darunavir-viatris-epar-product-information_is.pdf)

italiano (IT) (1.08 MB - PDF)

**First published:**

03/02/2017

**Last updated:**

11/12/2025

[View](/it/documents/product-information/darunavir-viatris-epar-product-information_it.pdf)

latviešu valoda (LV) (1.25 MB - PDF)

**First published:**

03/02/2017

**Last updated:**

11/12/2025

[View](/lv/documents/product-information/darunavir-viatris-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.2 MB - PDF)

**First published:**

03/02/2017

**Last updated:**

11/12/2025

[View](/lt/documents/product-information/darunavir-viatris-epar-product-information_lt.pdf)

magyar (HU) (1.12 MB - PDF)

**First published:**

03/02/2017

**Last updated:**

11/12/2025

[View](/hu/documents/product-information/darunavir-viatris-epar-product-information_hu.pdf)

Malti (MT) (1.28 MB - PDF)

**First published:**

03/02/2017

**Last updated:**

11/12/2025

[View](/mt/documents/product-information/darunavir-viatris-epar-product-information_mt.pdf)

Nederlands (NL) (1.2 MB - PDF)

**First published:**

03/02/2017

**Last updated:**

11/12/2025

[View](/nl/documents/product-information/darunavir-viatris-epar-product-information_nl.pdf)

norsk (NO) (1023.3 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

11/12/2025

[View](/no/documents/product-information/darunavir-viatris-epar-product-information_no.pdf)

polski (PL) (1.26 MB - PDF)

**First published:**

03/02/2017

**Last updated:**

11/12/2025

[View](/pl/documents/product-information/darunavir-viatris-epar-product-information_pl.pdf)

português (PT) (1.1 MB - PDF)

**First published:**

03/02/2017

**Last updated:**

11/12/2025

[View](/pt/documents/product-information/darunavir-viatris-epar-product-information_pt.pdf)

română (RO) (1.26 MB - PDF)

**First published:**

03/02/2017

**Last updated:**

11/12/2025

[View](/ro/documents/product-information/darunavir-viatris-epar-product-information_ro.pdf)

slovenčina (SK) (1.6 MB - PDF)

**First published:**

03/02/2017

**Last updated:**

11/12/2025

[View](/sk/documents/product-information/darunavir-viatris-epar-product-information_sk.pdf)

slovenščina (SL) (1.09 MB - PDF)

**First published:**

03/02/2017

**Last updated:**

11/12/2025

[View](/sl/documents/product-information/darunavir-viatris-epar-product-information_sl.pdf)

Suomi (FI) (1.02 MB - PDF)

**First published:**

03/02/2017

**Last updated:**

11/12/2025

[View](/fi/documents/product-information/darunavir-viatris-epar-product-information_fi.pdf)

svenska (SV) (1.02 MB - PDF)

**First published:**

03/02/2017

**Last updated:**

11/12/2025

[View](/sv/documents/product-information/darunavir-viatris-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0000315580 04/12/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Darunavir Viatris (previously Darunavir Mylan) : EPAR - All Authorised presentations

English (EN) (72.79 KB - PDF)

**First published:** 03/02/2017

**Last updated:** 24/05/2024

[View](/en/documents/all-authorised-presentations/darunavir-viatris-previously-darunavir-mylan-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-962)

български (BG) (114.64 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

24/05/2024

[View](/bg/documents/all-authorised-presentations/darunavir-viatris-previously-darunavir-mylan-epar-all-authorised-presentations_bg.pdf)

español (ES) (40.76 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

24/05/2024

[View](/es/documents/all-authorised-presentations/darunavir-viatris-previously-darunavir-mylan-epar-all-authorised-presentations_es.pdf)

čeština (CS) (79.94 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

24/05/2024

[View](/cs/documents/all-authorised-presentations/darunavir-viatris-previously-darunavir-mylan-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (39.5 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

24/05/2024

[View](/da/documents/all-authorised-presentations/darunavir-viatris-previously-darunavir-mylan-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (42.17 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

24/05/2024

[View](/de/documents/all-authorised-presentations/darunavir-viatris-previously-darunavir-mylan-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (79.33 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

24/05/2024

[View](/et/documents/all-authorised-presentations/darunavir-viatris-previously-darunavir-mylan-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (59.42 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

24/05/2024

[View](/el/documents/all-authorised-presentations/darunavir-viatris-previously-darunavir-mylan-epar-all-authorised-presentations_el.pdf)

français (FR) (79.26 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

24/05/2024

[View](/fr/documents/all-authorised-presentations/darunavir-viatris-previously-darunavir-mylan-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (78.65 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

24/05/2024

[View](/hr/documents/all-authorised-presentations/darunavir-viatris-previously-darunavir-mylan-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (39.63 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

24/05/2024

[View](/is/documents/all-authorised-presentations/darunavir-viatris-previously-darunavir-mylan-epar-all-authorised-presentations_is.pdf)

italiano (IT) (81.01 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

24/05/2024

[View](/it/documents/all-authorised-presentations/darunavir-viatris-previously-darunavir-mylan-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (103.93 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

24/05/2024

[View](/lv/documents/all-authorised-presentations/darunavir-viatris-previously-darunavir-mylan-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (109.46 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

24/05/2024

[View](/lt/documents/all-authorised-presentations/darunavir-viatris-previously-darunavir-mylan-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (104.81 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

24/05/2024

[View](/hu/documents/all-authorised-presentations/darunavir-viatris-previously-darunavir-mylan-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (81.12 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

24/05/2024

[View](/mt/documents/all-authorised-presentations/darunavir-viatris-previously-darunavir-mylan-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (79.06 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

24/05/2024

[View](/nl/documents/all-authorised-presentations/darunavir-viatris-previously-darunavir-mylan-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (47.79 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

24/05/2024

[View](/no/documents/all-authorised-presentations/darunavir-viatris-previously-darunavir-mylan-epar-all-authorised-presentations_no.pdf)

polski (PL) (64.25 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

24/05/2024

[View](/pl/documents/all-authorised-presentations/darunavir-viatris-previously-darunavir-mylan-epar-all-authorised-presentations_pl.pdf)

português (PT) (21.08 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

24/05/2024

[View](/pt/documents/all-authorised-presentations/darunavir-viatris-previously-darunavir-mylan-epar-all-authorised-presentations_pt.pdf)

română (RO) (77.51 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

24/05/2024

[View](/ro/documents/all-authorised-presentations/darunavir-viatris-previously-darunavir-mylan-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (59.01 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

24/05/2024

[View](/sk/documents/all-authorised-presentations/darunavir-viatris-previously-darunavir-mylan-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (61.91 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

24/05/2024

[View](/sl/documents/all-authorised-presentations/darunavir-viatris-previously-darunavir-mylan-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (84.63 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

24/05/2024

[View](/fi/documents/all-authorised-presentations/darunavir-viatris-previously-darunavir-mylan-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (45.05 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

24/05/2024

[View](/sv/documents/all-authorised-presentations/darunavir-viatris-previously-darunavir-mylan-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Darunavir Viatris (previously Darunavir Mylan) Active substance darunavir International non-proprietary name (INN) or common name darunavir Therapeutic area (MeSH) HIV Infections Anatomical therapeutic chemical (ATC) code J05AE10

### Pharmacotherapeutic group

Antivirals for systemic use

### Therapeutic indication

Darunavir, co-administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (HIV-1) infection (see section 4.2).

Darunavir Viatris 75 mg, 150 mg, 300 mg and 600 mg tablets may be used to provide suitable dose regimens (see section 4.2):

- For the treatment of HIV-1 infection in antiretroviral treatment (ART)-experienced adult patients, including those that have been highly pre-treated.
- For the treatment of HIV-1 infection in paediatric patients from the age of 3 years and at least 15 kg body weight.

In deciding to initiate treatment with darunavir co-administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. Genotypic or phenotypic testing (when available) and treatment history should guide the use of darunavir (see sections 4.2, 4.4 and 5.1).

Darunavir co-administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (HIV-1) infection.

Darunavir co-administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg) (see section 4.2).

Darunavir Viatris 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of HIV-1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are:

- antiretroviral therapy (ART)-naïve (see section 4.2).
- ART-experienced with no darunavir resistance associated mutations (DRV-RAMs) and who have plasma HIV-1 RNA &lt; 100,000 copies/ml and CD4+ cell count ? 100 cells x 10?/L. In deciding to initiate treatment with darunavir in such ART-experienced patients, genotypic testing should guide the use of darunavir (see sections 4.2, 4.3, 4.4 and 5.1).

## Authorisation details

EMA product number EMEA/H/C/004068

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Viatris Limited

Damastown Industrial Park Dublin 15 Ireland

Opinion adopted 14/09/2016 Marketing authorisation issued 03/01/2017 Revision 17

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Darunavir Viatris (previously Darunavir Mylan) : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (151.3 KB - PDF)

**First published:** 24/05/2024

**Last updated:** 11/12/2025

[View](/en/documents/procedural-steps-after/darunavir-viatris-previously-darunavir-mylan-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Darunavir Mylan : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (182.56 KB - PDF)

**First published:** 05/07/2017

**Last updated:** 13/05/2024

[View](/en/documents/procedural-steps-after/darunavir-mylan-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Darunavir Mylan : EPAR - Public assessment report

Adopted

Reference Number: EMA/851324/2016

English (EN) (533.19 KB - PDF)

**First published:** 03/02/2017

**Last updated:** 03/02/2017

[View](/en/documents/assessment-report/darunavir-mylan-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Darunavir Mylan

Adopted

Reference Number: EMA/CHMP/573531/2016

English (EN) (82.34 KB - PDF)

**First published:** 11/11/2016

**Last updated:** 11/11/2016

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-darunavir-mylan_en.pdf)

#### News on Darunavir Viatris (previously Darunavir Mylan)

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 7-10 November 2016](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-7-10-november-2016) 11/11/2016

#### More information on Darunavir Mylan

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-754)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

#### Related information

- [Clinical data](https://clinicaldata.ema.europa.eu/web/cdp/home?p_p_id=cdpdossierviewportlet_WAR_cdpdossierviewportlet=0=maximized=view=column-3=2=EMEAHC0040680000) (initial marketing authorisation)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 11/12/2025

## Share this page

[Back to top](#main-content)